<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35538489</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1757-2215</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>15</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of ovarian research</Title>
          <ISOAbbreviation>J Ovarian Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>MS: Wip1 suppresses angiogenesis through the STAT3-VEGF signalling pathway in serous ovarian cancer.</ArticleTitle>
        <Pagination>
          <StartPage>56</StartPage>
          <MedlinePgn>56</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">56</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13048-022-00990-6</ELocationID>
        <Abstract>
          <AbstractText>Multifaceted functions of the so-called "oncogene" Wip1 have been reported in a previous study, while its actual role remains to be explored in serous ovarian cancer (SOC). In this study, by performing bioinformatic analysis with a public database and immunohistochemical staining of Wip1 in tumour tissue from SOC, we concluded that decreased expression of Wip1 was associated with a higher rate of tumour metastasis and platinum-based therapy resistance and increased ascites volume, which led to poorer prognosis in SOC patients. We also found that overexpression of Wip1 in SKOV3 cells decreased the levels of several cytokines, including VEGF, by secretome profiling analysis, and Wip1 overexpression suppressed angiogenesis both in vitro and in vivo. Mechanistic studies indicated that overexpression of Wip1 decreased the expression of VEGF at both the protein and mRNA levels and that the inhibitory effect was mediated by dephosphorylation of STAT3 at Ser727. Our study uncovered the role of Wip1 in SOC and provides a novel therapeutic strategy for suppressing angiogenesis.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Yin</LastName>
            <ForeName>Sheng</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynaecologic Oncology, Ovarian Cancer Program, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Yang</LastName>
            <ForeName>Lina</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Yiyan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynaecologic Oncology, Ovarian Cancer Program, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zang</LastName>
            <ForeName>Rongyu</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynaecologic Oncology, Ovarian Cancer Program, Zhongshan Hospital, Fudan University, Shanghai, China. zang.rongyu@zs-hospital.sh.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Ovarian Res</MedlineTA>
        <NlmUniqueID>101474849</NlmUniqueID>
        <ISSNLinking>1757-2215</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C494086">STAT3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C467484">VEGFA protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.3.16</RegistryNumber>
          <NameOfSubstance UI="C000607458">PPM1D protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.3.16</RegistryNumber>
          <NameOfSubstance UI="D000071636">Protein Phosphatase 2C</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000077216" MajorTopicYN="N">Carcinoma, Ovarian Epithelial</DescriptorName>
          <QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018284" MajorTopicYN="Y">Cystadenocarcinoma, Serous</DescriptorName>
          <QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009389" MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010051" MajorTopicYN="Y">Ovarian Neoplasms</DescriptorName>
          <QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071636" MajorTopicYN="Y">Protein Phosphatase 2C</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050796" MajorTopicYN="Y">STAT3 Transcription Factor</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042461" MajorTopicYN="Y">Vascular Endothelial Growth Factor A</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Angiogenesis</Keyword>
        <Keyword MajorTopicYN="N">Inflammation</Keyword>
        <Keyword MajorTopicYN="N">STAT3</Keyword>
        <Keyword MajorTopicYN="N">Serous ovarian cancer</Keyword>
        <Keyword MajorTopicYN="N">Wip1</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>23</Hour>
          <Minute>38</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35538489</ArticleId>
        <ArticleId IdType="pmc">PMC9087943</ArticleId>
        <ArticleId IdType="doi">10.1186/s13048-022-00990-6</ArticleId>
        <ArticleId IdType="pii">10.1186/s13048-022-00990-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Siegel RL, et al.  Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi: 10.3322/caac.21654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21654</ArticleId>
            <ArticleId IdType="pubmed">33433946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marchetti C, et al.  Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments. Semin Cancer Biol. 2021;77:144–166. doi: 10.1016/j.semcancer.2021.08.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcancer.2021.08.011</ArticleId>
            <ArticleId IdType="pubmed">34464704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12(1):31–46. doi: 10.1158/2159-8290.CD-21-1059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-21-1059</ArticleId>
            <ArticleId IdType="pubmed">35022204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moon SH, et al.  Dephosphorylation of gamma-H2AX by WIP1: an important homeostatic regulatory event in DNA repair and cell cycle control. Cell Cycle. 2010;9(11):2092–2096. doi: 10.4161/cc.9.11.11810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cc.9.11.11810</ArticleId>
            <ArticleId IdType="pmc">PMC3984036</ArticleId>
            <ArticleId IdType="pubmed">20495376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shreeram S, et al.  Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol Cell. 2006;23(5):757–764. doi: 10.1016/j.molcel.2006.07.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2006.07.010</ArticleId>
            <ArticleId IdType="pubmed">16949371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bulavin DV, et al.  Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet. 2002;31(2):210–215. doi: 10.1038/ng894.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng894</ArticleId>
            <ArticleId IdType="pubmed">12021785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, et al.  Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet. 2002;31(2):133–134. doi: 10.1038/ng888.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng888</ArticleId>
            <ArticleId IdType="pubmed">12021784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fuku T, et al.  Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma. Pathol Int. 2007;57(9):566–571. doi: 10.1111/j.1440-1827.2007.02140.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1440-1827.2007.02140.x</ArticleId>
            <ArticleId IdType="pubmed">17685927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Satoh N, et al.  Oncogenic phosphatase Wip1 is a novel prognostic marker for lung adenocarcinoma patient survival. Cancer Sci. 2011;102(5):1101–1106. doi: 10.1111/j.1349-7006.2011.01898.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1349-7006.2011.01898.x</ArticleId>
            <ArticleId IdType="pubmed">21281403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Integrated genomic analyses of ovarian carcinoma  Nature. 2011;474(7353):609–615. doi: 10.1038/nature10166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature10166</ArticleId>
            <ArticleId IdType="pmc">PMC3163504</ArticleId>
            <ArticleId IdType="pubmed">21720365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin S, et al.  Wip1 suppresses ovarian cancer metastasis through the ATM/AKT/Snail mediated signaling. Oncotarget. 2016;7(20):29359–29370. doi: 10.18632/oncotarget.8833.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.8833</ArticleId>
            <ArticleId IdType="pmc">PMC5045401</ArticleId>
            <ArticleId IdType="pubmed">27121065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goloudina AR, et al.  Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents. Proc Natl Acad Sci U S A. 2012;109(2):E68–75. doi: 10.1073/pnas.1107017108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1107017108</ArticleId>
            <ArticleId IdType="pmc">PMC3258624</ArticleId>
            <ArticleId IdType="pubmed">22065775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu G, et al.  Phosphatase Wip1 negatively regulates neutrophil development through p38 MAPK-STAT1. Blood. 2013;121(3):519–529. doi: 10.1182/blood-2012-05-432674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2012-05-432674</ArticleId>
            <ArticleId IdType="pubmed">23212517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruark E, et al.  Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature. 2013;493(7432):406–410. doi: 10.1038/nature11725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature11725</ArticleId>
            <ArticleId IdType="pmc">PMC3759028</ArticleId>
            <ArticleId IdType="pubmed">23242139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, et al.  Fibrillin-1, induced by Aurora-A but inhibited by BRCA2, promotes ovarian cancer metastasis. Oncotarget. 2015;6(9):6670–6683. doi: 10.18632/oncotarget.3118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.3118</ArticleId>
            <ArticleId IdType="pmc">PMC4466642</ArticleId>
            <ArticleId IdType="pubmed">25749384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goloudina AR, et al.  Wip1 sensitizes p53-negative tumors to apoptosis by regulating the Bax/Bcl-xL ratio. Cell Cycle. 2012;11(10):1883–1887. doi: 10.4161/cc.19901.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cc.19901</ArticleId>
            <ArticleId IdType="pmc">PMC3359118</ArticleId>
            <ArticleId IdType="pubmed">22544321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clausse V, et al.  Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy. Cell Death Dis. 2016;7:e2195. doi: 10.1038/cddis.2016.96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2016.96</ArticleId>
            <ArticleId IdType="pmc">PMC4855675</ArticleId>
            <ArticleId IdType="pubmed">27077811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vuletic A, et al.  Cross-Talk Between Tumor Cells Undergoing Epithelial to Mesenchymal Transition and Natural Killer Cells in Tumor Microenvironment in Colorectal Cancer. Front Cell Dev Biol. 2021;9:750022. doi: 10.3389/fcell.2021.750022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcell.2021.750022</ArticleId>
            <ArticleId IdType="pmc">PMC8631470</ArticleId>
            <ArticleId IdType="pubmed">34858978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chattopadhyay I, Ambati R, Gundamaraju R. Exploring the Crosstalk between Inflammation and Epithelial-Mesenchymal Transition in Cancer. Mediators Inflamm. 2021;2021:9918379. doi: 10.1155/2021/9918379.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2021/9918379</ArticleId>
            <ArticleId IdType="pmc">PMC8219436</ArticleId>
            <ArticleId IdType="pubmed">34220337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chew J, et al.  WIP1 phosphatase is a negative regulator of NF-kappaB signalling. Nat Cell Biol. 2009;11(5):659–666. doi: 10.1038/ncb1873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb1873</ArticleId>
            <ArticleId IdType="pubmed">19377466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun B, et al.  Phosphatase Wip1 negatively regulates neutrophil migration and inflammation. J Immunol. 2014;192(3):1184–1195. doi: 10.4049/jimmunol.1300656.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1300656</ArticleId>
            <ArticleId IdType="pubmed">24395919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Q, et al.  Wip 1 inhibits intestinal inflammation in inflammatory bowel disease. Cell Immunol. 2016;310:63–70. doi: 10.1016/j.cellimm.2016.07.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellimm.2016.07.012</ArticleId>
            <ArticleId IdType="pubmed">27687530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uyanik B, et al.  DNA damage-induced phosphatase Wip1 in regulation of hematopoiesis, immune system and inflammation. Cell Death Discov. 2017;3:17018. doi: 10.1038/cddiscovery.2017.18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddiscovery.2017.18</ArticleId>
            <ArticleId IdType="pmc">PMC5377063</ArticleId>
            <ArticleId IdType="pubmed">28417018</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
